Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer
Teresa Sadras,Mickaël Martin,Kohei Kume,Mark E Robinson,Supraja Saravanakumar,Gal Lenz,Zhengshan Chen,Joo Y Song,Tanya Siddiqi,Laura Oksa,Anne Marie Knapp,Jevon Cutler,Kadriye Nehir Cosgun,Lars Klemm,Veronika Ecker,Janet Winchester,Dana Ghergus,Pauline Soulas-Sprauel,Friedemann Kiefer,Nora Heisterkamp,Akhilesh Pandey,Vu Ngo,Lili Wang,Hassan Jumaa,Maike Buchner,Jürgen Ruland,Wing-Chung Chan,Eric Meffre,Thierry Martin,Markus Müschen,Mark E. Robinson,Joo Y. Song
DOI: https://doi.org/10.1016/j.molcel.2021.03.043
IF: 16
2021-04-01
Molecular Cell
Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Summary</h2><p>Even though SYK and ZAP70 kinases share high sequence homology and serve analogous functions, their expression in B and T cells is strictly segregated throughout evolution. Here, we identified aberrant ZAP70 expression as a common feature in a broad range of B cell malignancies. We validated SYK as the kinase that sets the thresholds for negative selection of autoreactive and premalignant clones. When aberrantly expressed in B cells, ZAP70 competes with SYK at the BCR signalosome and redirects SYK from negative selection to tonic PI3K signaling, thereby promoting B cell survival. In genetic mouse models for B-ALL and B-CLL, conditional expression of Zap70 accelerated disease onset, while genetic deletion impaired malignant transformation. Inducible activation of Zap70 during B cell development compromised negative selection of autoreactive B cells, resulting in pervasive autoantibody production. Strict segregation of the two kinases is critical for normal B cell selection and represents a central safeguard against the development of autoimmune disease and B cell malignancies.</p>
cell biology,biochemistry & molecular biology